Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers

Maitham A. Moslim; Mengying Deng; Elizabeth Handorf; Stephanie H. Greco; Jeffrey M. Farma

doi:10.1016/j.amjsurg.2021.05.007

Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers

Maitham A. Moslim, Mengying Deng, Elizabeth Handorf, Stephanie H. Greco, Jeffrey M. Farma

Fox Chase Cancer Center

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Western literature lacks large-scale population studies comparing the influence of academic and high-volume (HV) versus low-volume (LV) cancer centers on gastric cancer oncologic outcomes. Methods: The National Cancer Database from 2004 to 2016 was used. Results: 22871 patients were studied. Patients with stage III signet-ring cell gastric carcinoma (SRGC) received neoadjuvant treatment (NAT) more frequently at academic and HV comprehensive cancer centers (OR: 4.27 and 2.42; p < 0.0001 and 0.009) compared to community centers. Patients with stage III non-SRGC (NSRGC) had a 2.4 times higher odds of receiving NAT at academic centers. The R1 resection rate for NSRGC was lower at academic centers (OR: 0.67; p = 0.0018). Lymph node harvest ≥15 nodes was 1.6 and 1.9 times higher at academic centers for NSRGC and SRGC, respectively. Patients treated at academic centers had a significantly improved overall survival (OS). Conclusions: Treatment at academic centers is associated with significant improvements in oncologic metrics and OS.

Original language	English
Pages (from-to)	969-975
Number of pages	7
Journal	American Journal of Surgery
Volume	222
Issue number	5
DOIs	https://doi.org/10.1016/j.amjsurg.2021.05.007
State	Published - Nov 2021

Keywords

Academic Medical Centers/standards
Adult
Aged
Aged, 80 and over
Carcinoma, Signet Ring Cell/mortality
Female
Humans
Male
Middle Aged
Quality of Health Care
Retrospective Studies
Stomach Neoplasms/mortality
Survival Analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.amjsurg.2021.05.007

Cite this

@article{2701aa1b8d6f420cbdc6d3f57411909a,

title = "Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers",

abstract = "Background: Western literature lacks large-scale population studies comparing the influence of academic and high-volume (HV) versus low-volume (LV) cancer centers on gastric cancer oncologic outcomes. Methods: The National Cancer Database from 2004 to 2016 was used. Results: 22871 patients were studied. Patients with stage III signet-ring cell gastric carcinoma (SRGC) received neoadjuvant treatment (NAT) more frequently at academic and HV comprehensive cancer centers (OR: 4.27 and 2.42; p < 0.0001 and 0.009) compared to community centers. Patients with stage III non-SRGC (NSRGC) had a 2.4 times higher odds of receiving NAT at academic centers. The R1 resection rate for NSRGC was lower at academic centers (OR: 0.67; p = 0.0018). Lymph node harvest ≥15 nodes was 1.6 and 1.9 times higher at academic centers for NSRGC and SRGC, respectively. Patients treated at academic centers had a significantly improved overall survival (OS). Conclusions: Treatment at academic centers is associated with significant improvements in oncologic metrics and OS.",

keywords = "Academic Medical Centers/standards, Adult, Aged, Aged, 80 and over, Carcinoma, Signet Ring Cell/mortality, Female, Humans, Male, Middle Aged, Quality of Health Care, Retrospective Studies, Stomach Neoplasms/mortality, Survival Analysis",

author = "Moslim, {Maitham A.} and Mengying Deng and Elizabeth Handorf and Greco, {Stephanie H.} and Farma, {Jeffrey M.}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = nov,

doi = "10.1016/j.amjsurg.2021.05.007",

language = "English",

volume = "222",

pages = "969--975",

journal = "American Journal of Surgery",

issn = "0002-9610",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers

AU - Moslim, Maitham A.

AU - Deng, Mengying

AU - Handorf, Elizabeth

AU - Greco, Stephanie H.

AU - Farma, Jeffrey M.

PY - 2021/11

Y1 - 2021/11

N2 - Background: Western literature lacks large-scale population studies comparing the influence of academic and high-volume (HV) versus low-volume (LV) cancer centers on gastric cancer oncologic outcomes. Methods: The National Cancer Database from 2004 to 2016 was used. Results: 22871 patients were studied. Patients with stage III signet-ring cell gastric carcinoma (SRGC) received neoadjuvant treatment (NAT) more frequently at academic and HV comprehensive cancer centers (OR: 4.27 and 2.42; p < 0.0001 and 0.009) compared to community centers. Patients with stage III non-SRGC (NSRGC) had a 2.4 times higher odds of receiving NAT at academic centers. The R1 resection rate for NSRGC was lower at academic centers (OR: 0.67; p = 0.0018). Lymph node harvest ≥15 nodes was 1.6 and 1.9 times higher at academic centers for NSRGC and SRGC, respectively. Patients treated at academic centers had a significantly improved overall survival (OS). Conclusions: Treatment at academic centers is associated with significant improvements in oncologic metrics and OS.

AB - Background: Western literature lacks large-scale population studies comparing the influence of academic and high-volume (HV) versus low-volume (LV) cancer centers on gastric cancer oncologic outcomes. Methods: The National Cancer Database from 2004 to 2016 was used. Results: 22871 patients were studied. Patients with stage III signet-ring cell gastric carcinoma (SRGC) received neoadjuvant treatment (NAT) more frequently at academic and HV comprehensive cancer centers (OR: 4.27 and 2.42; p < 0.0001 and 0.009) compared to community centers. Patients with stage III non-SRGC (NSRGC) had a 2.4 times higher odds of receiving NAT at academic centers. The R1 resection rate for NSRGC was lower at academic centers (OR: 0.67; p = 0.0018). Lymph node harvest ≥15 nodes was 1.6 and 1.9 times higher at academic centers for NSRGC and SRGC, respectively. Patients treated at academic centers had a significantly improved overall survival (OS). Conclusions: Treatment at academic centers is associated with significant improvements in oncologic metrics and OS.

KW - Academic Medical Centers/standards

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Carcinoma, Signet Ring Cell/mortality

KW - Female

KW - Humans

KW - Male

KW - Middle Aged

KW - Quality of Health Care

KW - Retrospective Studies

KW - Stomach Neoplasms/mortality

KW - Survival Analysis

UR - http://www.scopus.com/inward/record.url?scp=85108572676&partnerID=8YFLogxK

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000752594200024&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1016/j.amjsurg.2021.05.007

DO - 10.1016/j.amjsurg.2021.05.007

M3 - Article

C2 - 34045068

SN - 0002-9610

VL - 222

SP - 969

EP - 975

JO - American Journal of Surgery

JF - American Journal of Surgery

IS - 5

ER -

Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Biostatistics and Bioinformatics Facility

Cite this

Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Equipment

Biostatistics and Bioinformatics Facility

Cite this